We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MO Lifts 2026 EPS Outlook as Pricing Offsets Cigarette Volume Declines
Read MoreHide Full Article
Key Takeaways
Altria raises its 2026 EPS outlook to $5.66-$5.74, implying 4.5-6% growth from 2025 adjusted earnings.
MO's smokeable revenues rise 3.7% as stronger pricing offsets lower cigarette volumes and higher costs.
Altria's on! shipments grow 13.3%, but declining pouch market share and NJOY ACE's absence pose challenges.
Altria Group, Inc. (MO - Free Report) raised its 2026 earnings outlook after third-quarter pricing and profit growth helped offset another decline in cigarette shipments. The update keeps the focus on whether the company can sustain earnings growth as the U.S. combustible market contracts.
That balance is becoming more important as Altria invests in nicotine pouches and works through the continued absence of NJOY ACE from the U.S. market.
Altria Group, Inc. Price, Consensus and EPS Surprise
Altria now expects 2026 earnings of $5.66-$5.74 per share, up from its prior range of $5.61-$5.72. The new outlook implies 4.5%-6% growth from 2025 adjusted earnings of $5.42 per share.
The increase followed a 4.8% rise in third-quarter adjusted earnings to $1.52 per share and 5.1% growth for the first nine months. Management said the stronger year-to-date performance and confidence in the full-year plan supported the guidance increase.
Smokeable revenues net of excise taxes increased 3.7% in the third quarter, while adjusted operating companies income rose 3.9% to $3.07 billion. The adjusted margin expanded 10 basis points to 64.5%.
Higher pricing and increased refunds of taxes and duties on imported cigarettes drove the improvement. Those benefits outweighed lower shipment volume, higher promotional spending, an unfavorable mix shift and higher manufacturing costs. Smokeable price realization was 4.4% in the quarter.
MO Still Has to Outrun Falling Cigarette Demand
Domestic cigarette shipment volume declined 2.9% on a reported basis in the third quarter. Excluding trade inventory movements, Altria estimated that shipments fell about 4%, versus an estimated 5% decline for the overall industry.
Affordability pressure remains visible in the mix. Industry discount retail share reached 34.1%, up 2 percentage points year over year, while Altria's discount-brand shipments increased 40.5%. Marlboro's overall retail share fell 1 percentage point from a year earlier to 39.5%.
Altria's Next Growth Engine Remains a Work in Progress
on! shipments increased 13.3% to 47.8 million cans, while nicotine pouches expanded to 61.2% of the oral tobacco category. Still, on!'s share of the nicotine pouch category fell 1.3 percentage points to 13.5%, and Oral Tobacco Products adjusted operating companies income declined 3.7%.
The competitive backdrop is also getting tougher. Philip Morris International Inc. (PM - Free Report) said smoke-free products generated more than 40% of third-quarter 2026 net revenues, while its ZYN portfolio continued expanding. British American Tobacco p.l.c. (BTI - Free Report) reported 18% New Category revenue growth in the first half of 2026, driven by Modern Oral and U.S. vapor.
NJOY ACE remains another constraint. Altria's 2026 guidance assumes the product does not return to the marketplace this year, leaving nicotine pouches to carry more of the near-term smoke-free growth burden.
Image Source: Zacks Investment Research
MO's Ratings Frame the Guidance Upside
The raised outlook supports the near-term earnings case, but it does not remove the structural challenge of replacing declining cigarette volumes with profitable smoke-free growth. Altria still depends heavily on pricing, mix management and cost discipline to protect earnings.
MO currently carries a Zacks Rank #2 (Buy). The current-year earnings estimate has increased 0.4% over the past four weeks, which is consistent with a favorable earnings-revision backdrop. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock has a Value Score of D, Growth Score of C, Momentum Score of F and VGM Score of F. Those scores are less supportive than the A or B grades typically favored alongside a top Zacks Rank, suggesting investors should weigh the positive estimate trend against weaker value, growth and momentum characteristics.
Image: Bigstock
MO Lifts 2026 EPS Outlook as Pricing Offsets Cigarette Volume Declines
Key Takeaways
Altria Group, Inc. (MO - Free Report) raised its 2026 earnings outlook after third-quarter pricing and profit growth helped offset another decline in cigarette shipments. The update keeps the focus on whether the company can sustain earnings growth as the U.S. combustible market contracts.
That balance is becoming more important as Altria invests in nicotine pouches and works through the continued absence of NJOY ACE from the U.S. market.
Altria Group, Inc. Price, Consensus and EPS Surprise
Altria Group, Inc. price-consensus-eps-surprise-chart | Altria Group, Inc. Quote
MO Raises Its Full-Year Earnings Range
Altria now expects 2026 earnings of $5.66-$5.74 per share, up from its prior range of $5.61-$5.72. The new outlook implies 4.5%-6% growth from 2025 adjusted earnings of $5.42 per share.
The increase followed a 4.8% rise in third-quarter adjusted earnings to $1.52 per share and 5.1% growth for the first nine months. Management said the stronger year-to-date performance and confidence in the full-year plan supported the guidance increase.
Altria's Pricing Drives Stronger Smokeable Results
Smokeable revenues net of excise taxes increased 3.7% in the third quarter, while adjusted operating companies income rose 3.9% to $3.07 billion. The adjusted margin expanded 10 basis points to 64.5%.
Higher pricing and increased refunds of taxes and duties on imported cigarettes drove the improvement. Those benefits outweighed lower shipment volume, higher promotional spending, an unfavorable mix shift and higher manufacturing costs. Smokeable price realization was 4.4% in the quarter.
MO Still Has to Outrun Falling Cigarette Demand
Domestic cigarette shipment volume declined 2.9% on a reported basis in the third quarter. Excluding trade inventory movements, Altria estimated that shipments fell about 4%, versus an estimated 5% decline for the overall industry.
Affordability pressure remains visible in the mix. Industry discount retail share reached 34.1%, up 2 percentage points year over year, while Altria's discount-brand shipments increased 40.5%. Marlboro's overall retail share fell 1 percentage point from a year earlier to 39.5%.
Altria's Next Growth Engine Remains a Work in Progress
on! shipments increased 13.3% to 47.8 million cans, while nicotine pouches expanded to 61.2% of the oral tobacco category. Still, on!'s share of the nicotine pouch category fell 1.3 percentage points to 13.5%, and Oral Tobacco Products adjusted operating companies income declined 3.7%.
The competitive backdrop is also getting tougher. Philip Morris International Inc. (PM - Free Report) said smoke-free products generated more than 40% of third-quarter 2026 net revenues, while its ZYN portfolio continued expanding. British American Tobacco p.l.c. (BTI - Free Report) reported 18% New Category revenue growth in the first half of 2026, driven by Modern Oral and U.S. vapor.
NJOY ACE remains another constraint. Altria's 2026 guidance assumes the product does not return to the marketplace this year, leaving nicotine pouches to carry more of the near-term smoke-free growth burden.
Image Source: Zacks Investment Research
MO's Ratings Frame the Guidance Upside
The raised outlook supports the near-term earnings case, but it does not remove the structural challenge of replacing declining cigarette volumes with profitable smoke-free growth. Altria still depends heavily on pricing, mix management and cost discipline to protect earnings.
MO currently carries a Zacks Rank #2 (Buy). The current-year earnings estimate has increased 0.4% over the past four weeks, which is consistent with a favorable earnings-revision backdrop. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock has a Value Score of D, Growth Score of C, Momentum Score of F and VGM Score of F. Those scores are less supportive than the A or B grades typically favored alongside a top Zacks Rank, suggesting investors should weigh the positive estimate trend against weaker value, growth and momentum characteristics.